Q4 EPS Estimates for TG Therapeutics Increased by Analyst

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at HC Wainwright increased their Q4 2025 earnings per share (EPS) estimates for shares of TG Therapeutics in a research note issued to investors on Wednesday, January 14th. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will post earnings per share of $0.27 for the quarter, up from their prior forecast of $0.20. HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ FY2027 earnings at $1.92 EPS.

TGTX has been the topic of a number of other research reports. JPMorgan Chase & Co. raised their price objective on shares of TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of TG Therapeutics in a report on Wednesday. The Goldman Sachs Group boosted their price objective on shares of TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a research report on Thursday. B. Riley raised TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. Finally, Wall Street Zen raised TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, December 14th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, TG Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $50.75.

TG Therapeutics Stock Up 4.0%

TG Therapeutics stock opened at $30.71 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.82 and a quick ratio of 2.89. TG Therapeutics has a 1-year low of $25.28 and a 1-year high of $46.48. The stock has a market cap of $4.88 billion, a PE ratio of 11.05 and a beta of 1.86. The stock’s fifty day moving average is $30.80 and its two-hundred day moving average is $32.56.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $2.19. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The firm had revenue of $161.71 million for the quarter, compared to analyst estimates of $152.12 million. During the same period in the prior year, the firm earned $0.02 earnings per share. The business’s quarterly revenue was up 92.7% compared to the same quarter last year.

Institutional Trading of TG Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada raised its holdings in TG Therapeutics by 16.4% during the first quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company’s stock worth $2,985,000 after acquiring an additional 10,660 shares in the last quarter. NewEdge Advisors LLC raised its holdings in shares of TG Therapeutics by 9.6% in the 1st quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company’s stock valued at $299,000 after purchasing an additional 665 shares during the period. Goldman Sachs Group Inc. lifted its stake in TG Therapeutics by 21.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after purchasing an additional 345,059 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in TG Therapeutics by 5.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company’s stock worth $11,319,000 after purchasing an additional 14,689 shares during the period. Finally, Strs Ohio acquired a new position in TG Therapeutics during the first quarter worth approximately $785,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other TG Therapeutics news, Director Yann Echelard sold 5,000 shares of the business’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $32.57, for a total transaction of $162,850.00. Following the completion of the sale, the director owned 223,816 shares in the company, valued at $7,289,687.12. The trade was a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.64% of the stock is currently owned by insiders.

TG Therapeutics News Roundup

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Goldman Sachs highlighted a stronger Briumvi sales trajectory and said there’s room for a sizable rally, which helped renew investor confidence. TG Therapeutics stock pops as Briumvi boom reignites bull case
• Positive Sentiment: Preliminary Q4/2025 results and updated 2025 sales guidance beat expectations, reinforcing revenue momentum from Briumvi and supporting the bullish narrative. TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results
• Positive Sentiment: Unusually large call-option buying (a big jump in call volume) and reports of retail traders piling in have amplified upside momentum and intraday volume — a technical/flow-driven bullish signal for short-term trading. Retail traders are piling into TG Therapeutics – what’s driving the chatter?
• Neutral Sentiment: HC Wainwright kept a Buy rating and a $60 target but made several small tweaks to multi-year EPS forecasts — raising FY2025 estimates while trimming FY2026–FY2030 numbers marginally. That keeps a constructive long-term analyst anchor but introduces modest near-term estimate risk. (Market commentary summary; no direct article link)
• Negative Sentiment: Bank of America Securities moved to a Sell on TGTX, which adds a notable bearish institutional view that could cap the rally or trigger profit-taking by more cautious investors. TG Therapeutics (TGTX) Receives a Sell from Bank of America Securities

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.